Physician profile
Lara Bitar
NPI 1407532344
$1,426.84
in general payments reported to CMS, 2019-2025
13 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $857 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.58 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $275.72 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Genzyme Corporation | $244.20 | 2024 | |
| Janssen Scientific Affairs, LLC | $149.99 | 2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $143.04 | 2025 | Fasenra |
| Boston Scientific Corporation | $120.00 | 2025 | Watchman Flx |
| Averitas Pharma INC. | $47.31 | 2025 | Qutenza |
| Inari Medical, INC. | $44.20 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Actelion Pharmaceuticals US, INC. | $35.33 | 2024 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.38 | 2024 | Jardiance |
| Kestra Medical Technology Services, INC. | $23.74 | 2024 | Assure Wcd |
| Recor Medical INC | $17.35 | 2024 | Paradise Renal Denervation System |
| Dynavax Technologies Corporation | $9.00 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Bitar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.